Fedratinib: First Approval
- 30 September 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 79 (15), 1719-1725
- https://doi.org/10.1007/s40265-019-01205-x
Abstract
Fedratinib (INREBIC®) is a JAK2-selective inhibitor that has been developed as an oral treatment for myelofibrosis. In August 2019, fedratinib received its first global approval in the USA for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. Phase III clinical development for myelofibrosis is ongoing worldwide. This article summarizes the milestones in the development of fedratinib leading to this first approval for myelofibrosis.Keywords
This publication has 21 references indexed in Scilit:
- High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasmsLaboratory Investigation, 2014
- Effect of food on the bioavailability and tolerability of the JAK2‐selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteersClinical Pharmacology in Drug Development, 2014
- The Janus Kinase 2 Inhibitor Fedratinib Inhibits Thiamine Uptake: A Putative Mechanism for the Onset of Wernicke’s EncephalopathyDrug Metabolism and Disposition, 2014
- Erratum: Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)Leukemia, 2014
- A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteersThe Journal of Clinical Pharmacology, 2013
- Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)Leukemia, 2013
- Abstract 1796: SAR302503: A Jak2 inhibitor with antitumor activity in solid tumor modelsCancer Research, 2012
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in MyelofibrosisJournal of Clinical Oncology, 2011
- JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitationsLeukemia, 2010
- Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia VeraCancer Cell, 2008